Perceptive Informatics launches new medical imaging methodology

Perceptive Informatics, an eClinical solutions provider and a subsidiary of Parexel International, has developed a new medical imaging methodology for central nervous system clinical trials involving Alzheimer’s disease.

The method, based on measuring ventricular size, provides a new approach to monitor brain atrophy in Alzheimer’s disease and potential treatment effects, said Parexel.

According to Parexel, the advantages of this method include providing higher quality, reproducible, and regulatory compliant assessments with the potential to help clinical trial sponsors make better and faster development decisions about Alzheimer’s treatments in development.

To develop this method, the Perceptive Informatics team collected magnetic resonance imaging scans from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database using Perceptive’s medical imaging system and regulatory compliant processes.

James Paskavitz, medical director of Perceptive Informatics, said: Based on ADNI data, measuring ventricular change may be one of the most robust outcomes for imaging progression of Alzheimer’s disease. Perceptive has developed a novel method of ventricular measurement that accurately reflects brain atrophy.

We believe that this method can support sponsors in reducing the time, cost and risk associated with clinical development of Alzheimer’s treatments by providing medical image data that informs early phase decisions and is reproducible for later phase, multi-center trials.